Skip to content

Study of Buprenorphine augmentation in regular treatment of resistant obsessive compulsive disorder

Study of Buprenorphine augmentation in regular treatment of resistant obsessive compulsive disorder

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015062422901N1
Enrollment
23
Registered
2015-12-06
Start date
2015-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive compulsive disorder. Obsessive compulsive disorder

Interventions

Intervention 1: Tablet Buprenorphine 250 mg would be prescribed daily for 8 weeks and increased 500mg weekly with respect to patient tolerance. Intervention 2: The regular treatment is to start with a
Treatment - Drugs
Tablet Buprenorphine 250 mg would be prescribed daily for 8 weeks and increased 500mg weekly with respect to patient tolerance
The regular treatment is to start with an SSRI (Selective Serotonin Reuptake Inhibitors) or clomipramine for 4 to 6 weeks . If treatment with clomipramine or an SSRI Is unsuccessful, many therapists

Sponsors

Vice chancellor of research of Hamadan university of medical scienses
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) patients with primary Obsessive Compulsive Disorder who received minimum of 2 different Selective Serotonin Reuptake Inhibitor for a period of 16 weeks in two separate rotations but failed to respond to treatment (less than 25% in symptom regression); (b)age between 18 to 60 years old; (c) scores of more than 16 according to Yale-Brown Obsessive Compulsive Scale (Y-COBS) Exclusion criteria: (a) receiving any other opioid medications; (b) having any history of alcohol or substance abuse; (c) received any electroconvulsive therapy during the last two months; (d) having any serious diseases which require long term medical treatment such as diabetes, high blood pressure, rheumatoid arthritis, cardiovascular diseases, respiratory diseases, thyroid diseases or gastrointestinal diseases; (e) any signs of psychotic disorders, such as bi-polar schizophrenia or similar; (f)being at a great risk of suicide attempt; (g) any pregnant woman or any woman who intend pregnancy during the next 3 months; (h) any serious- non psychological diseases; (i)any upcoming surgery which needs anesthesia or deep Sedation; (j) patient is a candidate to receive electroconvulsive therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Obsessive Compulsive Disorder severity. Timepoint: before intervention and end of 1,2,3,4,5 weeks after that. Method of measurement: Yale Brown Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amin Reihani

Hamadan University of Medical Sciences

dr.reihani.a@gmail.com+98 81 3827 1066

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026